Novel Hapten Design and Prediction Model Construct for Immunodetection of Benzimidazole Derivative: Emergence of Broad-Spectrum Antibody for Monitoring

Zile Wang,Liang Zhang,YanHong Yang,Huixia Zhang,Zhenhui Ren,Weichunbai Zhang,Pimiao Zheng,Haiyang Jiang

DOI: https://doi.org/10.2139/ssrn.4096121

2022-01-01

SSRN Electronic Journal

Abstract:Benzimidazole anthelmintics (BZs) were commonly used for the treatment of soil-transmitted helminth infections in human and veterinary clinics, but the abuse of BZs and their metabolites have potential damage to the environment and human health; thus, the monitoring of BZs in various samples should be strengthened. In this study, a "zero epitope loss" strategy was first adopted for hapten design, and a broad-spectrum antibody capable of recognizing more than twenty BZs was obtained, with half-inhibitory concentrations (IC 50 ) at the picogram level. Based on the quantitative structure-activity relationship (QSAR) of BZs, 3D-QSAR and Holographic QSAR models (q 2 >0.72, r 2 >0.99) were established to explain and predict the potential recognition ability of BZs by the antibody and showed good prediction results for four additional BZs, which further proved that the R1 group on the skeleton of benzimidazole played a decisive role. An indirect competitive ELISA was established as an application of immunodetection, and it was used for rapid detection of albendazole and its metabolites (ABZs) in milk with a one-step pretreatment (mean recovery rate 74.68%-116.21%), which showed the obtained antibody could be further used in the development of various immunological methods for simultaneous detection of BZs.